DEF 14A: Phio Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split and Incentive Plan Expansion

Phio Pharmaceuticals is asking stockholders to vote on proposals including a reverse stock split to maintain Nasdaq listing and an increase in shares available under its long-term incentive plan.

Summary

• Phio Pharmaceuticals Corp. has scheduled its 2024 Annual Meeting of Stockholders for June 17, 2024, to be held virtually.
• Stockholders will vote on several proposals, including the election of five directors, ratification of BDO USA, P.C. as the independent accounting firm, and an amendment to the company's charter to effect a reverse stock split.
• The reverse stock split would be at a ratio of not less than 1-for-2 and not greater than 1-for-9, with the exact ratio to be determined by the Board of Directors.
• Another proposal involves amending and restating the 2020 Long Term Incentive Plan to increase the number of shares available for issuance by 500,000.
• The Board of Directors unanimously recommends voting FOR each nominee and proposal.

Sentiment

Score: 6

Explanation: The document is primarily procedural, but the need for a reverse stock split suggests underlying financial challenges. The positive aspect is the proactive approach to maintaining Nasdaq listing and incentivizing employees.

Positives

• The proposed reverse stock split aims to maintain the company's Nasdaq listing, which could improve investor confidence.
• Increasing the shares available under the 2020 Long Term Incentive Plan could help attract and retain key employees.
• The Board of Directors is actively addressing the minimum bid price requirement from Nasdaq.
• The company is using electronic delivery of proxy materials to reduce costs and environmental impact.

Negatives

• The reverse stock split could be viewed negatively by the market and may not result in a proportional increase in share price.
• There is no guarantee that the reverse stock split will maintain the share price above $1.00.
• The reverse stock split may result in some stockholders owning odd lots, which can be more difficult to sell.
• If the reverse stock split is not implemented within 12 months, the authority to do so will terminate.

Risks

• Failure to maintain a minimum bid price of $1.00 per share could result in delisting from the Nasdaq Capital Market.
• Delisting could adversely affect the company's ability to raise additional financing and the liquidity of its common stock.
• The reverse stock split may not attract new investors or improve trading liquidity.
• The increased proportion of unissued authorized shares could have an anti-takeover effect.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement and continue to provide stock-based incentives to employees.

Management Comments

• Robert Bitterman, President and CEO, cordially invites stockholders to attend the Annual Meeting.
• The Board of Directors has unanimously approved the proposals and recommends a vote FOR each nominee and proposal.

Industry Context

The document reflects common corporate governance practices, including seeking stockholder approval for key decisions like reverse stock splits and executive compensation plans, particularly for companies needing to maintain listing requirements.

Comparison to Industry Standards

• The structure of the board and its committees (Audit, Compensation, Nominating, and Governance) aligns with standard corporate governance practices for publicly traded companies, similar to companies like Amgen, Biogen, and Gilead Sciences.
• The director compensation structure, including cash retainers and equity grants, is comparable to that of other small-cap biotechnology companies.
• The proposed reverse stock split is a common strategy for companies facing delisting from major stock exchanges, as seen with companies like Ocugen and Evofem Biosciences.
• The long-term incentive plan and its proposed amendment are typical tools used by biotechnology companies to attract and retain talent, similar to plans offered by companies like Moderna and BioNTech.

Stakeholder Impact

• Shareholders will be directly impacted by the reverse stock split and the potential dilution from increased shares available under the incentive plan.
• Employees may benefit from the amended incentive plan, which could improve motivation and retention.
• The company's ability to raise capital and fund operations could be affected by the outcome of the proposals.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The Board of Directors will determine the exact ratio of the reverse stock split if approved.
• The company will file a Certificate of Amendment to effect the reverse stock split if approved and implemented by the board.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, incentive plan, stockholders, directors, compensation, governance, Nasdaq, PHIO